Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)

Trial Profile

An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs LSC-2 (Primary)
  • Indications Limbal stem cell deficiency
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RHEACELL
  • Most Recent Events

    • 24 Jan 2019 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.
    • 24 Jan 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Sep 2020.
    • 24 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top